Janux Therapeutics
JANX
48 hedge funds and large institutions have $370M invested in Janux Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 10 closing their positions.
2,420% more call options, than puts
Call options by funds: $630K | Put options by funds: $25K
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
3.51% more ownership
Funds ownership: 69.5% → 73.01% (+3.5%)
3% less capital invested
Capital invested by funds: $381M → $370M (-$11.8M)
4% less funds holding
Funds holding: 50 → 48 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$40.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.31M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$1.92M |
| 4 |
BlackRock
New York
|
+$526K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$521K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.74M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$6.13M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$5.88M |
| 4 |
E
Ergoteles
New York
|
-$416K |
| 5 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$283K |
JANX Hedge Fund Activity: Q1 2023 in Review
48 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2023, worth a combined $370M — down 3.1% from $381M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of JANX and 8 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, adding an estimated $40.2M. The largest seller was Fidelity Investments, cutting an estimated $7.74M.
- 48 institutional investors held Janux Therapeutics (JANX) as of Q1 2023, down from 50 in Q4 2022.
- Funds reported $370M of Janux Therapeutics stock for Q1 2023, down 3.1% quarter-over-quarter.
- 8 funds opened new Janux Therapeutics positions in Q1 2023 and 10 closed out, a net change of -2 holders.
- The largest Janux Therapeutics buyer in Q1 2023 was EcoR1 Capital, an estimated $40.2M added.
- The largest Janux Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $7.74M sold.
Based on aggregated 13F filings for Q1 2023.